Clifford Swan Investment Counsel LLC Sells 6,415 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Clifford Swan Investment Counsel LLC lowered its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 55.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,190 shares of the company's stock after selling 6,415 shares during the quarter. Clifford Swan Investment Counsel LLC's holdings in GE HealthCare Technologies were worth $406,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Kohmann Bosshard Financial Services LLC purchased a new position in GE HealthCare Technologies in the 4th quarter valued at about $45,000. Smartleaf Asset Management LLC lifted its holdings in shares of GE HealthCare Technologies by 30.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,883 shares of the company's stock worth $148,000 after acquiring an additional 435 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of GE HealthCare Technologies by 6.9% during the 4th quarter. Fisher Asset Management LLC now owns 3,624 shares of the company's stock worth $283,000 after acquiring an additional 233 shares during the period. Bank OZK purchased a new position in shares of GE HealthCare Technologies during the 4th quarter worth about $1,700,000. Finally, SVB Wealth LLC purchased a new position in shares of GE HealthCare Technologies during the 4th quarter worth about $417,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on GEHC shares. Jefferies Financial Group raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and increased their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Wells Fargo & Company raised their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Finally, Citigroup raised their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, GE HealthCare Technologies has an average rating of "Moderate Buy" and an average price target of $97.67.

Remove Ads

GE HealthCare Technologies Stock Up 0.4 %

GE HealthCare Technologies stock traded up $0.34 during midday trading on Thursday, reaching $85.10. The stock had a trading volume of 1,999,776 shares, compared to its average volume of 2,909,880. The firm's fifty day simple moving average is $86.52 and its 200-day simple moving average is $86.13. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80. The stock has a market capitalization of $38.91 billion, a P/E ratio of 19.60, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $5.32 billion during the quarter, compared to analysts' expectations of $5.33 billion. As a group, analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.